심장 POC 검사 장비 시장 예측(2026-2032년)

The Cardiac POC Testing Devices Market is projected to grow by USD 3.78 billion at a CAGR of 6.69% by 2032.

Cardiac point-of-care testing (POC testing) devices are reshaping acute cardiovascular diagnostics by enabling rapid measurement of biomarkers such as cardiac troponin, creatine kinase-MB, myoglobin, D-dimer, B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide, and other indicators used in emergency departments, ambulances, urgent care centers, intensive care units, and primary care settings. Their core value lies in shortening the time between symptom presentation, diagnostic interpretation, triage, and treatment initiation for suspected acute coronary syndrome, heart failure, thromboembolic events, and related cardiac conditions. The clinical need is well established: cardiovascular diseases remain the leading cause of death globally, and early diagnosis is central to reducing avoidable complications.

The executive landscape for cardiac POC testing devices is defined by three converging priorities: faster clinical decision-making, decentralized diagnostics, and measurable quality outcomes. High-sensitivity troponin testing has become central to chest pain pathways, while portable analyzers and connected testing platforms are increasingly aligned with hospital digital infrastructure, emergency medical services, and remote care models. However, adoption depends on analytical accuracy, regulatory compliance, quality control, operator training, reimbursement pathways, cybersecurity, and interoperability with electronic health records. As healthcare systems push diagnostics closer to the patient, cardiac POC testing devices are becoming essential tools for improving workflow efficiency, reducing diagnostic delays, and supporting evidence-based cardiovascular care.

Transformative Shifts in the Cardiac POC Testing Landscape

The cardiac POC testing devices landscape is undergoing transformative change as care delivery shifts from centralized laboratory dependence toward near-patient diagnostics. Emergency departments are prioritizing faster rule-in and rule-out protocols for myocardial infarction, while ambulatory and community-based settings are using rapid cardiac biomarkers to support earlier referrals and risk stratification. This shift is especially relevant in overcrowded hospitals, rural health systems, and regions with limited access to advanced laboratory infrastructure.

Technology transformation is being driven by miniaturized immunoassay platforms, improved biosensor performance, cartridge-based testing, multiplex biomarker panels, microfluidics, and wireless connectivity. Devices are increasingly designed to integrate with hospital information systems, laboratory information systems, middleware, and cloud-based quality management tools. Regulatory expectations are also shaping innovation, with greater emphasis on analytical sensitivity, clinical validation, operator competency, traceability, lot management, and post-market performance monitoring.

Another important shift is the growing role of decentralized care pathways. Paramedic-led testing, urgent care diagnostics, home-based cardiac monitoring support, and primary care triage are expanding the relevance of cardiac POC testing beyond traditional hospital environments. At the same time, healthcare providers are scrutinizing total cost of care, repeat testing rates, turnaround time, patient throughput, and adherence to evidence-based chest pain and heart failure protocols. As a result, future competitiveness will depend less on standalone device speed and more on clinically integrated solutions that combine accuracy, usability, connectivity, and workflow reliability.

Cumulative Impact of Artificial Intelligence on Cardiac POC Testing

Artificial intelligence is beginning to influence cardiac POC testing devices through decision support, automated interpretation, quality assurance, and predictive analytics. AI-enabled algorithms can assist clinicians by combining POC biomarker results with electrocardiogram findings, patient history, vital signs, age, sex, renal function, comorbidities, and validated risk scores to support more consistent triage decisions. This is particularly important in chest pain evaluation, where rapid but accurate differentiation between myocardial infarction, unstable angina, non-cardiac chest pain, heart failure exacerbation, pulmonary embolism, and other conditions is clinically critical.

AI can also strengthen operational performance. Automated quality control monitoring, anomaly detection, lot-to-lot variability analysis, connectivity diagnostics, environmental condition tracking, and operator performance monitoring help reduce preventable errors in decentralized testing environments. In high-volume emergency care settings, AI-enabled workflow tools can prioritize critical results, flag repeat testing intervals, and support compliance with clinical protocols.

The cumulative impact of AI will depend on validation, transparency, cybersecurity, data governance, and clinician trust. Cardiac diagnostics carry high clinical consequences, so AI outputs must be explainable, evidence-based, and aligned with regulatory requirements for software used in medical decision support. The most valuable applications will not replace clinical judgment; they will improve consistency, reduce cognitive burden, and connect cardiac POC testing data with broader cardiovascular risk management pathways.

Key Regional Insights for Cardiac POC Testing Devices

Asia-Pacific is advancing rapidly as a critical region for cardiac POC testing devices due to rising cardiovascular disease burden, expanding hospital infrastructure, aging populations in several countries, and government efforts to improve access to diagnostics across urban and rural settings. China, India, Japan, South Korea, and Australia are strengthening emergency cardiac care pathways, while many Southeast Asian countries are investing in decentralized diagnostic capacity to reduce referral delays. Demand is supported by large patient populations, increasing diabetes and hypertension prevalence, and a growing emphasis on early detection of acute coronary syndrome and heart failure.

Europe is characterized by strict regulatory expectations, established clinical guidelines, and broad use of high-sensitivity cardiac biomarkers in acute care. Germany, France, the United Kingdom, Italy, and Spain emphasize clinical validation, data protection, interoperability, and post-market surveillance within hospital networks. North America remains one of the most mature environments for cardiac POC testing adoption, supported by established emergency medicine protocols, high utilization of cardiac biomarkers, advanced laboratory accreditation systems, and strong integration of diagnostics with electronic health records. The United States and Canada emphasize rapid triage, reduced emergency department congestion, and evidence-based chest pain pathways, making analytical performance, connectivity, and quality oversight key purchasing criteria.

Latin America is seeing increased relevance for cardiac POC testing as healthcare systems address uneven access to centralized laboratories and emergency cardiac care. Brazil and Mexico are important contributors, with growing hospital modernization and public health attention toward noncommunicable diseases. Africa's need is shaped by limited laboratory access in many settings, rising cardiovascular risk factors, and the value of portable, durable, easy-to-use devices suitable for decentralized and resource-constrained environments. The Middle East is investing in advanced emergency care infrastructure, particularly in countries with national healthcare transformation programs, where rapid cardiac biomarker testing aligns with digital health, ambulance services, and hospital modernization priorities.

Key Group Insights Across NATO, G7, BRICS, EU, ASEAN, and GCC

NATO member countries include many high-income healthcare systems where emergency preparedness, interoperable health infrastructure, standardized procurement, and resilient supply chains influence decisions for cardiac POC testing devices. The group's emphasis on healthcare continuity, crisis readiness, and connected systems strengthens the relevance of rapid cardiac diagnostics in hospitals, military medical settings, emergency response networks, and cross-border care pathways. G7 countries generally demonstrate advanced adoption conditions due to mature healthcare systems, strong clinical guideline implementation, established reimbursement mechanisms, accredited laboratory oversight, and extensive emergency care infrastructure.

BRICS countries represent a diverse but strategically significant group, with China, India, Brazil, Russia, and South Africa facing large cardiovascular disease burdens and varying levels of diagnostic decentralization. These countries share a need for scalable, cost-conscious, and reliable cardiac POC testing models that can function across tertiary hospitals, regional clinics, and underserved areas. The European Union provides a highly regulated environment where device performance, clinical evidence, data security, quality management, and post-market surveillance are central to adoption. Alignment with medical device regulatory frameworks, laboratory quality standards, and privacy requirements is essential for access and sustained use.

ASEAN countries are increasingly important for cardiac POC testing devices because they combine rising cardiovascular disease prevalence with diverse healthcare access conditions. Urban hospitals in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines are adopting faster diagnostic workflows, while rural, island, and cross-border geographies strengthen the case for portable cardiac testing that can support earlier referral decisions. The GCC region is prioritizing advanced healthcare infrastructure, digital health integration, and emergency care modernization. Countries in the Gulf are addressing high rates of diabetes, obesity, and hypertension, which are major cardiovascular risk factors, making rapid cardiac biomarker testing relevant for both emergency and chronic disease pathways.

Key Country Insights for Cardiac POC Testing Devices

China is expanding cardiac diagnostic capacity through hospital investment, domestic innovation, and rising demand for rapid acute care diagnostics, while the United States is a leading adopter of cardiac POC testing devices due to high emergency care utilization for chest pain, widespread use of cardiac troponin testing, and strong demand for faster triage. Japan emphasizes high-quality diagnostics, aging population needs, and advanced emergency care systems, whereas India presents strong need for accessible cardiac POC testing because of its high cardiovascular disease burden, large rural population, and increasing private healthcare penetration.

Germany has a strong hospital-based diagnostics environment and prioritizes analytical reliability, clinical evidence, and regulatory compliance, while the United Kingdom focuses on emergency care efficiency, chest pain pathway optimization, and integration of diagnostics into national health service delivery. Australia benefits from well-structured clinical governance and the value of POC testing in remote and rural health services. France emphasizes clinical evidence, healthcare quality, connected medical technologies, and strict data protection requirements. South Korea combines advanced hospital infrastructure, digital health adoption, and a strong focus on rapid, high-quality cardiovascular care.

Italy and Spain continue to rely on guideline-driven cardiac biomarker testing within emergency and hospital care, with growing interest in digital connectivity and workflow efficiency. Canada emphasizes standardized care pathways, laboratory quality oversight, and equitable access across geographically dispersed populations. Russia's adoption is influenced by regional healthcare disparities and the need to improve acute cardiovascular diagnostics across large geographies. Brazil is shaped by a large public and private healthcare mix and a significant burden of ischemic heart disease, while Mexico is expanding diagnostic access through hospital modernization and greater attention to cardiovascular risk management.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical-grade performance, workflow integration, and evidence-based differentiation. The most actionable strategy is to design cardiac POC testing devices that meet emergency care requirements for speed while maintaining laboratory-aligned accuracy, traceability, and quality control. High-sensitivity biomarker capability, simplified cartridge handling, low sample volume, rapid turnaround time, robust onboard controls, and clear result interpretation are essential for adoption in both hospital and decentralized settings.

Manufacturers and healthcare stakeholders should invest in interoperability with electronic health records, laboratory information systems, middleware, and remote quality management platforms. Connected diagnostics can improve result visibility, reduce manual documentation errors, support audit readiness, strengthen clinical governance, and enable standardized oversight across multiple care locations. In parallel, organizations should develop training programs for nurses, paramedics, general practitioners, emergency clinicians, and non-laboratory operators to ensure consistent test performance.

Regulatory strategy should begin early, with clinical validation plans aligned to intended use, setting of care, specimen type, operator profile, and relevant patient populations. Industry leaders should also build resilient supply chains for cartridges, reagents, calibrators, quality controls, and consumables, as cardiac POC testing depends on uninterrupted availability. Finally, partnerships with healthcare systems should focus on measurable outcomes such as reduced time to diagnosis, improved triage accuracy, shorter emergency department length of stay, fewer avoidable transfers, and better adherence to chest pain and heart failure protocols.

Research Methodology

This executive summary is developed using a structured secondary research methodology focused on verified, data-backed sources relevant to cardiac POC testing devices and cardiovascular diagnostics. The research approach includes review of publicly available clinical guidelines, regulatory publications, hospital care pathway literature, peer-reviewed studies, public health databases, device safety communications, laboratory quality standards, and healthcare policy documents. Emphasis is placed on sources that address cardiac biomarkers, point-of-care testing quality standards, acute coronary syndrome triage, heart failure diagnostics, emergency medicine workflows, decentralized healthcare delivery, and digital health integration.

The methodology applies triangulation across clinical, regulatory, technological, and regional evidence to ensure balanced interpretation. Insights are assessed for relevance to device adoption, care setting, testing workflow, analytical performance, operator requirements, connectivity, cybersecurity, quality management, and patient care impact. Regional, group, and country insights are synthesized from observable healthcare infrastructure trends, cardiovascular disease burden, diagnostic access priorities, clinical guideline adoption, and regulatory environments. The analysis intentionally excludes market sizing, revenue estimation, market share calculation, and forecasting to maintain a qualitative, evidence-oriented perspective focused on strategic decision-making.

Conclusion

Cardiac POC testing devices are becoming indispensable in modern cardiovascular care as healthcare systems seek faster, more accessible, and clinically reliable diagnostic pathways. Their role is expanding from emergency departments to ambulances, urgent care centers, rural clinics, and integrated chronic disease management settings. The strongest adoption drivers include the global burden of cardiovascular disease, the clinical importance of early myocardial infarction and heart failure detection, pressure to reduce diagnostic delays, and the need for decentralized testing solutions.

The future direction of the field will be defined by high-sensitivity biomarker performance, AI-supported interpretation, digital connectivity, regulatory compliance, cybersecurity, and quality management across distributed care environments. Regions and countries differ in infrastructure maturity, reimbursement conditions, and clinical workflow readiness, but the underlying need is consistent: rapid cardiac diagnostics that support timely, accurate, and actionable decisions. Industry leaders that combine analytical excellence with usability, interoperability, validated clinical value, and resilient supply chains will be best positioned to support the next generation of cardiac point-of-care testing.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cardiac POC Testing Devices Market, by Product Type

• 7.1. Introduction
• 7.2. BNP
• 7.3. CK-MB
• 7.4. Myoglobin
• 7.5. Troponin
  • 7.5.1. Troponin I
  • 7.5.2. Troponin T

8. Cardiac POC Testing Devices Market, by Sample Type

• 8.1. Introduction
• 8.2. Plasma
• 8.3. Serum
• 8.4. Whole Blood

9. Cardiac POC Testing Devices Market, by Technology

• 9.1. Introduction
• 9.2. Colorimetric
• 9.3. Electrochemical
• 9.4. Immunoassay
  • 9.4.1. Fluorescence
  • 9.4.2. Lateral Flow

10. Cardiac POC Testing Devices Market, by Application

• 10.1. Introduction
• 10.2. Acute Coronary Syndrome Diagnosis
• 10.3. Myocardial Infarction Detection
• 10.4. Heart Failure Monitoring
• 10.5. Cardiac Risk Assessment

11. Cardiac POC Testing Devices Market, by End User

• 11.1. Introduction
• 11.2. Clinics
• 11.3. Diagnostic Laboratories
• 11.4. Hospital
  • 11.4.1. Cardiac Care Unit
  • 11.4.2. Emergency Department

12. Cardiac POC Testing Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Cardiac POC Testing Devices Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Cardiac POC Testing Devices Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Acon Laboratories
• 16.3. Alfa Scientific Designs
• 16.4. Beckman Coulter
• 16.5. Becton Dickinson and Company
• 16.6. Bio-Rad Laboratories, Inc
• 16.7. Boditech Med Inc
• 16.8. Creative Diagnostics
• 16.9. Danaher Corporation
• 16.10. EKF Diagnostics Holdings
• 16.11. F. Hoffmann-La Roche Ltd
• 16.12. HemoCue AB
• 16.13. Krsnaa Diagnostics Ltd
• 16.14. Life Diagnostics, Inc
• 16.15. Lumina Diagnostics
• 16.16. Luminex Corporation
• 16.17. Lupin Diagnostics
• 16.18. Masimo Corporation
• 16.19. Medtronic
• 16.20. Meso Scale Diagnostics
• 16.21. Mindray
• 16.22. Nano-Ditech Corporation
• 16.23. Nova Biomedical Corporation
• 16.24. Pathkind Labs
• 16.25. QuidelOrtho Corporation
• 16.26. Randox Laboratories Ltd
• 16.27. Siemens Healthineers AG
• 16.28. Thermo Fisher Scientific Inc